Carvedilol sulfate - Jiangsu HengRui Medicine
Alternative Names: Carvedilol sulfate extended release - Jiangsu HengRui MedicineLatest Information Update: 07 Jan 2022
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Antioxidants; Beta adrenergic receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 26 Feb 2016 No development reported - Phase-III for Heart failure in China (PO)
- 26 Feb 2016 No development reported - Phase-III for Hypertension in China (PO)
- 31 Dec 2013 Phase-III clinical trials in Heart failure in China (PO)